Novel Vaccine Candidates against Tuberculosis

(E-pub Ahead of Print)

Author(s): Zhihao Li, Changping Zheng, Marco Terreni, Lisa Tanzi, Matthieu Sollogoub, Yongmin Zhang*.

Journal Name: Current Medicinal Chemistry

Submit Manuscript
Submit Proposal


Ranking above AIDS, tuberculosis (TB) is the ninth leading cause of death affecting and killing many individuals every year. Drugs' efficacy is limited by serials of problems such as multi-drug resistance (MDR) and extensively-drug resistance (XDR). Meanwhile, the only licensed vaccine BCG (Bacillus Calmette–Guérin) existing for over 90 years is not effective enough. Consequently, it is essential to develop novel vaccines for TB prevention and immunotherapy. This paper provides an overall review of the TB prevalence, immune system response against TB and recent progress of TB vaccine research and development. Several vaccines in clinical trials are described as well as LAM-based candidates.

Keywords: Tuberculosis, Vaccine, Lipoarabinomannan.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867326666181126112124
Price: $95